Abstract
Pralsetinib (PRL) is a selective Rearranged during Transfection (RET) inhibitor, developed by Blueprint Medicines Corporation for the treatment of RET fusion non-small-cell lung cancer (NSCLC), papillary thyroid cancer (PTC), and medullary thyroid carcinoma (MTC). RET is a known proto-oncogene found in NSCLC, PTC, and MTC. PRL was recently granted accelerated USFDA approval with the brand name GAVRETO™ on 4 September 2020 to treat metastatic RET fusion-positive NSCLC and was updated on 1 December 2020 with the addition of advanced and metastatic RET-altered MTC and PTC in the USA. On 19 November 2021, the European Commission granted conditional marketing authorization to PRL for use as a single agent in adult patients with RET fusion-positive advanced NSCLC. They were not previously treated with an RET inhibitor. This review article summarizes the milestones in the development of PRL, chemistry, chemical (synthesis) research and development, characterization and identification of PRL-resistant RET mutants, the structural basis of resistance to PRL, mechanism of action, pharmacokinetics, pharmacodynamic, adverse effects, and regulatory status, including ongoing clinical trial of PRL and other potential drug candidates, leading to this first approval of PRL for the treatment of various solid tumors (RET fusion NSCLC, MTC, and PTC).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersson E, Arvidsson Y, Sward C, Hofving T, Wangberg B, Kristiansson E, Nilsson O (2016) Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets. Mod Pathol 29:616–629. https://doi.org/10.1038/modpathol.2016.48
Andreucci E, Francica P, Fearns A, Martin LA, Chiarugi P, Isacke CM, Morandi A (2016) Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget 7:80543–80553. https://doi.org/10.18632/oncotarget
Awad M (2020) A study of alectinib in RET-rearranged non-small cell lung cancer or RET-mutated thyroid cancer. https://clinicaltrials.gov/ct2/show/NCT03131206?term=NCT03131206&draw=2&rank=1. Accessed 16 Mar 2020
Baglivo S, Ludovini V, Moretti R, Bellezza G, Sidoni A, Roila F, Metro G (2020) RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature. Oncol Ther 8:333–339. https://doi.org/10.1007/s40487-020-00116-2
Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, Reis-Filho JS, Subbiah V, Gainor JF, Endris V, Repetto M (2021) ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol 32:337–350. https://doi.org/10.1016/j.annonc.2020.11.021
Besse B, Felip E, Clifford C, Louie-Gao M, Green J, Turner CD, Popat S (2020) AcceleRET lung: a phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS9633
Besse B, Felip E, Kim ES, Clifford C, Louie-Gao M, Yagui-Beltran A, Popat S (2021) AcceleRET lung: a phase 3 study of first-line pralsetinib in patients with RET-fusion+ advanced/metastatic NSCLC. J Thorac Oncol 16:S44–S45. https://doi.org/10.1016/j.jtho.2020.10.087
Blueprint Medicines Corporation (BMC) (2020) Pre-approval access program (PAAP) for pralsetinib (BLU-667) in patients with unresectable or metastatic NSCLC or MTC. https://clinicaltrials.gov/ct2/show/NCTnn04204928?term=pralsetinib&draw=2&rank=2. Accessed 30 Sept 2020
Blueprint Medicines Corporation (BMC) (2021) External control, observational, retrospective study comparing pralsetinib to best available therapy in patients with RET-fusion positive NSCLC. https://clinicaltrials.gov/ct2/show/NCT04697446?term=pralsetinib&draw=2&rank=5. Accessed 31 May 2021
Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L (1995) RET activation by germline MEN2A and MEN2B mutations. Oncogene 11:2419–2427. https://pubmed.ncbi.nlm.nih.gov/8570194/
Boston Pharmaceuticals (BP) (2020) Safety, efficacy, and tolerability of BOS172738 in patients with advanced rearranged during transfection (RET) gene-altered tumors. https://clinicaltrials.gov/ct2/show/NCT03780517?term=NCT03780517&draw=2&rank=1. Accessed 16 Mar 2020
Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE (2008) The RET receptor tyrosine kinase pathway functionally interacts with the ERα pathway in breast cancer. Cancer Res 68:3743–3751. https://doi.org/10.1158/0008-5472
Brandhuber B, Haas J, Tuch B, Ebata K, Bouhana K, McFaddin E, Williams L, Winski S, Brown E, Burkhard M, Nanda N (2016) The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. Eur J Cancer 1:S144. https://doi.org/10.1016/S0959-8049(16)33028-3
Brooijmans N, DiPietro LV, Fleming PE, Kim JL, Wenglowsky SM, Zhang Y (2020) 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors. U.S. Patent 10,774,070. https://patents.google.com/patent/US10202365B2/en
Brubaker JD, Kim JL, Wilson KJ, Wilson D, Dipietro LV (2017) Inhibitors of RET. U.S. Patent Application 15/340,428. https://patents.google.com/patent/US20170121312A1/en
Brubaker JD, Kim JL, Wilson KJ, Wilson D, DiPietro LV (2018) Inhibitors of RET. U.S. Patent 10,030,005. https://patents.google.com/patent/US10030005B2/en
Brubaker JD, Kim JL, Wilson KJ, Wilson D, DiPietro LV (2020a) Inhibitors of RET. U.S. Patent 10,584,114. https://patents.google.com/patent/US10584114B2/en
Brubaker JD, Kim JL, Wilson KJ, Wilson D, Dipietro LV (2020b) Inhibitors of RET. U.S. Patent Application 16/775,646. https://patents.google.com/patent/US2020b0407341A1/en?oq=16%2f775%2c646
Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M (2003) Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 88:1897–1902. https://doi.org/10.1210/jc.2002-021278
Choudhury NJ, Drilon A (2020) Decade in review: a new era for RET-rearranged lung cancers. Transl Lung Cancer Res 9:2571. https://doi.org/10.21037/tlcr-20-346
Dabir S, Babakoohi S, Kluge A, Morrow JJ, Kresak A, Yang M, MacPherson D, Wildey G, Dowlati A (2014) RET mutation and expression in small-cell lung cancer. J Thorac Oncol 9:1316–1323. https://doi.org/10.1097/JTO.0000000000000234
Dagogo-Jack I, Stevens SE, Lin JJ, Nagy R, Ferris L, Shaw AT, Gainor JF (2018) Emergence of a RET V804M gatekeeper mutation during treatment with vandetanib in RET-rearranged NSCLC. J Thorac Oncol 13:e226–e227. https://doi.org/10.1016/j.jtho.2018.06.021
Daud A (2020) Capmatinib, ceritinib, regorafenib, or entrectinib in treating patients with BRAF/NRAS wild-type stage III–IV melanoma. https://clinicaltrials.gov/ct2/show/NCT02587650?term=NCT02587650&draw=2&rank=1. Accessed 16 Mar 2020
Drilon A, Hu ZI, Lai GGY, Tan DSW (2018) Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 15:151–167. https://doi.org/10.1038/nrclinonc.2017.175
Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP (2019) A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105. Cancer Discov 9:384–395. https://doi.org/10.1158/2159-8290.CD-18-0839
Drilon A, Oxnard GR, Tan DSW, Loong HH, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N (2020a) Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 383:813–824. https://doi.org/10.1056/NEJMoa2005653
Drilon A, Zhai D, Rogers E, Deng W, Zhang X, Ung J, Lee D, Rodon L, Graber A, Zimmerman Z, Subbiah V (2020b) The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models. J Clin Oncol 38:3616–3616. https://doi.org/10.1200/JCO.2020.38.15_suppl.3616
Eisai Inc. (2020) Study of the safety and activity of lenvatinib (E7080) in subjects with KIF5B-RET-positive adenocarcinoma of the lung. https://clinicaltrials.gov/ct2/show/NCT01877083?term=NCT01877083&draw=2&rank=1. Accessed 16 Mar 2020
El Osta B, Ramalingam SS (2020) RET fusion: joining the ranks of targetable molecular drivers in non-small cell lung cancer. JTO Clin Res Rep 1:100050. https://doi.org/10.1016/j.jtocrr.2020.100050
Eli Lilly and Company (ELC) (2021) A study of LOXO-292 in participants with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer. https://clinicaltrials.gov/ct2/show/NCT03157128?term=NCT03157128&draw=2&rank=1. Accessed 25 May 2021
Esseghir S, Todd SK, Hunt T, Poulsom R, Plaza-Menacho I, Reis-Filho JS, Isacke CM (2007) A role for glial cell–derived neurotrophic factor–induced expression by inflammatory cytokines and ret/gfrα1 receptor up-regulation in breast cancer. Cancer Res 67:11732–11741. https://doi.org/10.1158/0008-5472
European Thoracic Oncology Platform (ETOP) (2020) ALEctinib for the treatment of pretreated RET-rearranged advanced non-small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT03445000?term=NCT03445000&draw=2&rank=1. Accessed 16 Mar 2020
Fancelli S, Caliman E, Mazzoni F, Brugia M, Castiglione F, Voltolini L, Pillozzi S, Antonuzzo L (2021) Chasing the target: new phenomena of resistance to novel selective RET inhibitors in lung cancer. Updated evidence and future perspectives. Cancers 13:1091. https://doi.org/10.3390/cancers13051091
Gainor J, Curigliano G, Doebele RC, Lin JJ, Ou SHI, Miller S, Turner CD, Subbiah V (2020a) Analysis of resistance mechanisms to pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC) from the ARROW study. IASLC 2020 North American Conference on Lung Cancer 2020; Abstract OA05.02. https://www.blueprintmedicines.com/wp-content/uploads/2020/10/Blueprint-Medicines-IASLC-North-America-Pralsetinib-NSCLC-Resistance-Mechanisms-Presentation.pdf
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DS, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Clifford C, Zhang H, Turner CD, Subbiah V (2020b) Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.9515
Gainor JF, Curigliano G, Doebele RC, Lin JJ, Ou SH, Miller S, Turner CD, Subbiah V (2021a) OA05. 02 analysis of resistance mechanisms to pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC) from the ARROW study. J Thorac Oncol 16:S5. https://doi.org/10.1016/j.jtho.2020.10.027
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier P, Lopes G, Tan DW, Garralda E (2021b) MO01. 38 registrational dataset from the phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients with advanced RET fusion+ non-small-cell lung cancer (NSCLC). J Thorac Oncol 16:S31–S32. https://doi.org/10.1016/j.jtho.2020.10.142
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V (2021c) Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 22(7):959–969. https://doi.org/10.1016/S1470-2045(21)00247-3
Garraway L (2020) Gavreto, RET inhibitor, FDA approved for metastatic NSCLC with RET fusions. Am Health Drug Benefits 13:213–215. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7741173/pdf/ahdb-13-213.pdf
Gattelli A, Nalvarte I, Boulay A, Roloff TC, Schreiber M, Carragher N, Macleod KK, Schlederer M, Lienhard S, Kenner L, Torres-Arzayus MI (2013) Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol Med 5:1335–1350. https://doi.org/10.1002/emmm.201302625
Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J (2017) Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol 35:1403–1410. https://doi.org/10.1200/JCO.2016.70.9352
GAVRETO™ (pralsetinib) capsules, for oral use Initial U.S. Approval (2020) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf. Accessed 30 Oct 2021
Genentech, Inc. (2020) A study of alectinib, entrectinib, vemurafenib plus cobimetinib, or pralsetinib in patients with resectable stages II–III non-small cell lung cancer with ALK, ROS1, NTRK, BRAF V600, or RET molecular alterations. https://clinicaltrials.gov/ct2/show/NCT04302025?term=pralsetinib&draw=2&rank=6. Accessed 30 Sept 2020
Hatem R, Labiod D, Chateau-Joubert S, de Plater L, El Botty R, Vacher S, Bonin F, Servely JL, Dieras V, Bièche I, Marangoni E (2016) Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. Int J Cancer 138:2510–2521. https://doi.org/10.1002/ijc.29974
Hayashi T, Odintsov I, Smith RS, Ishizawa K, Liu AJ, Delasos L, Kurzatkowski C, Tai H, Gladstone E, Vojnic M, Kohsaka S (2021) RET inhibition in novel patient-derived models of RET fusion-positive lung adenocarcinoma reveals a role for MYC upregulation. Dis Model Mech 14:dmm047779. https://doi.org/10.1242/dmm.047779
Heeran D, Murray BJ, Qiu S, Martin SJ, Skelton RM, Dodds KR, Yufit DS, Sandford G (2021) Synthesis of polyfunctional fluoro-quinoline and fluoro-pyridopyrimidinone derivatives. J Fluor 249:109830. https://doi.org/10.1016/j.jfluchem.2021.109830
Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR Jr, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V (2020) Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799. https://doi.org/10.1136/esmoopen-2020-000799
Hoffmann-La Roche (HLR) (2018) Phase 1/2 study of the highly-selective RET inhibitor, pralsetinib (BLU-667), in patients with thyroid cancer, non-small cell lung cancer, and other advanced solid tumors (ARROW). https://clinicaltrials.gov/ct2/show/NCT03037385?term=pralsetinib&draw=2&rank=4. Accessed 30 Sept 2018
Hoffmann-La Roche (HLR) (2020a) Tumor-agnostic precision immuno-oncology and somatic targeting rational for you (TAPISTRY) platform study. https://clinicaltrials.gov/ct2/show/NCT04589845?term=pralsetinib&draw=2&rank=7. Accessed 30 Sept 2020
Hoffmann-La Roche (HLR) (2020b) A study of pralsetinib versus standard of care for first-line treatment of advanced non-small cell lung cancer (NSCLC) (AcceleRET-Lung). https://clinicaltrials.gov/ct2/show/NCT04222972?term=pralsetinib&draw=2&rank=3. Accessed 30 Sept 2020
Hoffmann-La Roche (HLR) (2021) A study of pralsetinib versus standard of care (SOC) for treatment of RET-mutated medullary thyroid cancer (MTC). (AcceleRET-MTC). https://clinicaltrials.gov/ct2/show/NCT04760288?term=pralsetinib&draw=2&rank=1. Accessed 30 May 2021
Hu M, Subbiah V, Wirth LJ, Schuler M, Mansfield AS, Brose MS, Curigliano G, Leboulleux S, Zhu VW, Keam B, Matos I (2020) 1913O results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Ann Oncol 31:S1084. https://doi.org/10.1016/j.annonc.2020.08.1401
Keam B, Hu MI, Subbiah V, Wirth L, Schuler M, Mansfield AS, Brose MS, Curigliano G, Leboulleux S, Zhu VW, Matos I (2020) 442P results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Anna Oncol 31:S1413–S1414. https://doi.org/10.1016/j.annonc.2020.10.434
Kim ST (2020) Study to evaluate the safety and efficacy of sunitinib, in subject with refractory solid tumors. https://clinicaltrials.gov/ct2/show/NCT02691793?term=NCT02691793&draw=2&rank=1. Accessed 31 Dec 2020
Kim M, Kim BH (2021) Current guidelines for management of medullary thyroid carcinoma. Endocrinol Metab (Seoul) 36(3):514–524. https://doi.org/10.3803/EnM.2021.1082
Kim JL, Wilson KJ, Brubaker JD (2019) Inhibitors of RET. U.S. Patent 10,183,928. https://patents.google.com/patent/US10183928B2/en?oq=U.S.+Patent+10%2c183%2c928
Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibáñez CF, McDonald NQ (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281:33577–33587. https://doi.org/10.1074/jbc.M605604200
Kohno T, Tabata J, Nakaoku T (2020) RET oma: a cancer subtype with a shared driver oncogene. Carcinogenesis 41:123–129. https://doi.org/10.1093/carcin/bgz184
Lawrence NF, Hammond MR, Frederick DT, Su Y, Dias-Santagata D, Deng A, Selim MA, Mahalingam M, Flaherty KT, Hoang MP (2016) Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): a clinicopathologic analysis of predictors of outcome. J Am Acad Dermatol 75:595–602. https://doi.org/10.1016/j.jaad.2016.04.059
Lee SH (2020) Vandetanib in advanced NSCLC with RET rearrangement. https://clinicaltrials.gov/ct2/show/NCT01823068?term=NCT01823068&draw=2&rank=1. Accessed 16 Mar 2020
Lee DH, Subbiah V, Gainor JF, Taylor MH, Zhu VW, Doebele RC, Lopes G, Baik C, Garralda E, Gadgeel SM, Kim DW, Turner CD, Palmer M, Miller S, Curigliano G (2019) Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Ann Oncol 30:ix122. https://doi.org/10.1093/annonc/mdz431
Lee YP, Jeong BH, Eun Y, Kang CI, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM (2021) Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: a Korean single-centre compassionate use experience. Eur J Cancer 159:167–173. https://doi.org/10.1016/j.ejca.2021.09.037
Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, Harris J (2017) Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations. Clin Cancer Res 23:2981–2990. https://doi.org/10.1158/1078-0432.CCR-16-1887
Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C (2019) RET fusions in solid tumors. Cancer Treat Rev 81:101911. https://doi.org/10.1016/j.ctrv.2019.101911
Liang X, Yang Q, Wu P, He C, Yin L, Xu F, Yin Z, Yue G, Zou Y, Li L, Song X (2021) The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020. Bioorg Chem 113:105011. https://doi.org/10.1016/j.bioorg.2021.105011
Lin JJ, Solomon BJ (2020) Reply to “Emergence of High Level of MET Amplification during Treatment with Selpercatinib in KIF5B-RET NSCLC.” J Thorac Oncol 15:e127–e128. https://doi.org/10.1016/j.jtho.2020.04.010
Lin JJ, Liu SV, McCoach CE, Zhu VW, Tan AC, Yoda S, Peterson J, Do A, Prutisto-Chang K, Dagogo-Jack I, Sequist LV, Wirth LJ, Lennerz JK, Hata AN, Mino-Kenudson M, Nardi V, Ou SHI, Tan DSW, Gainor JF (2020) Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 31:1725–1733. https://doi.org/10.1016/j.annonc.2020.09.015
Liu X, Shen T, Mooers BHM, Hilberg F, Wu J (2018) Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol 175:3504–3515. https://doi.org/10.1111/bph.14395
Liu X, Hu X, Shen T, Li Q, Mooers BH, Wu J (2020) RET kinase alterations in targeted cancer therapy. Cancer Drug Resist 3:472–481. https://doi.org/10.20517/cdr.2020.15
Liu J, Pandya P, Afshar S (2021) Therapeutic advances in oncology. Int J Mol Sci 22:2008–2015. https://doi.org/10.3390/ijms22042008
Liu AW, Liang C, Lee CS (2022) A contemporary review of rearranged during transfection-selective inhibitors. J Oncol Pharm Pract 28(1):175–184. https://doi.org/10.1177/10781552211040542
Locantore P, Novizio R, Corsello A, Paragliola RM, Pontecorvi A, Corsello SM (2022) Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer. Expert Opin Drug Discov 17(2):101–107. https://doi.org/10.1080/17460441.2022.1995351
Lorch JH (2020) The 2020 American Society of Clinical Oncology Conference: exciting new data on thyroid cancer. Clin Thyroidol 32:347–350. https://doi.org/10.1089/ct.2020;32.347-350
Margraf RL, Crockett DK, Krautscheid PM, Seamons R, Calderon FR, Wittwer CT, Mao R (2009) Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 30:548–556. https://doi.org/10.1002/humu.20928
Markham A (2020) Pralsetinib first approval. Drugs 80:1865–1870. https://doi.org/10.1007/s40265-020-01427-4
Marmarelis ME, Chiarle R, Ambrogio C, Aggarwal C (2020) A LIBRETTO to orchestrate targeted therapy. Nat Cancer 1:1038–1040. https://doi.org/10.1038/s43018-020-00144-x
Marx S (2005) Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5:367–375. https://doi.org/10.1038/nrc1610
Memorial Sloan Kettering Cancer Center (MSKCC) (2020a) Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions or increased MET or AXL activity. https://clinicaltrials.gov/ct2/show/NCT01639508?term=NCT01639508&draw=2&rank=1. Accessed 16 Mar 2020
Memorial Sloan Kettering Cancer Center (MSKCC) (2020b) Continued access to RXDX-105. https://clinicaltrials.gov/ct2/show/NCT03784378?term=NCT03784378&draw=2&rank=1. Accessed 31 Dec 2020
Montrone M, Longo V, Catino A, Pizzutilo P, Galetta D (2021) Efficacy of pralsetinib in a patient with advanced lung adenocarcinoma positive for RET rearrangement: the importance of Comprehensive Genomic Profiling. Recenti Prog Med 112:10e–13e. https://doi.org/10.1701/3525.35132
Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM (2013) GDNFRET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res 73:3783–3795. https://doi.org/10.1158/0008-5472.CAN-12-4265
Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles PP, Tsuchihara K, Matsumoto S, Shimada Y, Mimaki S, Ishii G (2018) A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat Commun 9:625. https://doi.org/10.1038/s41467-018-02994-7
Narita N, Tanemura A, Murali R, Scolyer RA, Huang S, Arigami T, Yanagita S, Chong KK, Thompson JF, Morton DL, Hoon DS (2009) Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 28:3058–3068. https://doi.org/10.1038/onc.2009.164
National Cancer Institute (NCI) (2020) Sunitinib malate in treating patients with thyroid cancer that did not respond to iodine I 131 and cannot be removed by surgery. https://clinicaltrials.gov/ct2/show/NCT00381641?cond=NCT00381641&draw=2&rank=1. Accessed 31 Dec 2020
National Cancer Institute (NCI) (2021a) Nivolumab, cabozantinib S-malate, and ipilimumab in treating patients with recurrent stage IV non-small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT03468985?term=NCT03468985&draw=2&rank=1. Accessed 25 May 2021
National Cancer Institute (NCI) (2021b) Dasatinib in treating patients with recurrent or metastatic malignant salivary gland tumors. https://clinicaltrials.gov/ct2/show/NCT00859937?term=00859937&draw=2&rank=1. Accessed 16 Mar 2020
National Taiwan University Hospital (NTUH) (2020) AUY922 in patient with stage IV NSCLC. https://clinicaltrials.gov/ct2/show/NCT01922583?term=NCT01922583&draw=2&rank=1. Accessed 16 Mar 2020
Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, Varella-Garcia M, Tan AC, Doebele RC (2017) Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling. Mol Cancer Ther 16:1623–1633. https://doi.org/10.1158/1535-7163.MCT-17-0008
Nguyen L, Monestime S (2021) Pralsetinib (Gavreto): treatment of metastatic non-small-cell lung cancer in patients positive for RET fusions. Am J Health Syst Pharm. https://doi.org/10.1093/ajhp/zxab462
Novartis Pharmaceuticals (NP) (2020) Dovitinib for patients with tumor pathway activations inhibited by dovitinib—full text view—ClinicalTrials.gov [Internet]. [cited 2015 December]. Available from https://clinicaltrials.gov/ct2/show/NCT01831726?term=NCT01831726&draw=2&rank=1. Accessed 16 Mar 2020
Ohshima Y, Yajima I, Takeda K, Iida M, Kumasaka M, Matsumoto Y, Kato M (2010) c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS ONE 5:e10279. https://doi.org/10.1371/journal.pone.0010279
Ou SH, Zhu VW (2020) Catalog of 5′ fusion partners in RET+ NSCLC circa 2020. JTO Clin Res Rep 1:100037. https://doi.org/10.1016/j.jtocrr.2020.100037
Papaila A, Jacobson AT (2021) Into the unknown: a case of new-onset cardiomyopathy in a patient treated with recently approved tyrosine kinase inhibitor, pralsetinib. Cureus 13(6):e15441. https://doi.org/10.7759/cureus.15441
Park JO (2020) Single-arm study to evaluate the safety and efficacy of sunitinib, in subjects with RET fusion positive or FGFR2 amplification, refractory solid tumors. https://clinicaltrials.gov/ct2/show/NCT02450123?term=NCT02450123&draw=2&rank=1. Accessed 31 Dec 2020
Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM (2010) Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 29:4648–4657. https://doi.org/10.1038/onc.2010.209
Rahal R, Maynard M, Hu W, Brubaker JD, Cao Q, Kim JL, Sheets MP, Wilson DP, Wilson KJ, DiPietro L, Fleming P (2018) BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers. In: Molecular cancer therapeutics, vol 17, no 1. American Association for Cancer Research, Philadelphia
Romei C, Ciampi R, Casella F, Tacito A, Torregrossa L, Ugolini C, Basolo F, Materazzi G, Vitti P, Elisei R (2018) RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget 9:9875–9884. https://doi.org/10.18632/oncotarget.23986
Rosen EY, Johnson ML, Clifford SE, Somwar R, Kherani JF, Son J, Bertram AA, Davare MA, Gladstone E, Ivanova EV, Henry DN (2020) Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res 27:34–42. https://doi.org/10.1158/1078-0432.CCR-20-2278
Russano M (2021) Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib. Recenti Prog Med 112:5e–9e. https://doi.org/10.1701/3525.35131
Saleh K, Khalife N, Felefly T (2021) RET-fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm. Future Oncol 17:1445–1448. https://doi.org/10.2217/fon-2020-1297
Salvatore D, Santoro M, Schlumberger M (2021) The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol 17:296–306. https://doi.org/10.1038/s41574-021-00470-9
Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381–383. https://doi.org/10.1126/science.7824936
Shaw A (2020) Ponatinib in advanced NSCLC w/RET translocations. https://clinicaltrials.gov/ct2/show/NCT01813734?term=NCT01813734&draw=2&rank=1. Accessed 16 Mar 2020
Shen T, Hu X, Liu X, Subbiah V, Mooers BHM, Wu J (2021) The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precis Oncol 5(1):48. https://doi.org/10.1038/s41698-021-00188-x
Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR (2020) RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol 15:541–549. https://doi.org/10.1016/j.jtho.2020.01.006
Spanheimer PM, Park JM, Askeland RW, Kulak MV, Woodfield GW, De Andrade JP, Cyr AR, Sugg SL, Thomas A, Weigel RJ (2014) Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer. Clin Cancer Res 20:2115–2125. https://doi.org/10.1158/1078-0432.CCR-13-2221
Subbiah V, Cote GJ (2020) Advances in targeting RET-dependent cancers. Cancer Discov 10:498–505. https://doi.org/10.1158/2159-8290.CD-19-1116
Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK (2018a) Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov 8:836–849. https://doi.org/10.1158/2159-8290.CD-18-0338
Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S (2018b) Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29:1869–1876. https://doi.org/10.1093/annonc/mdy137
Subbiah V, Hu MI, Gainor JF, Mansfield AS, Alonso G, Taylor MH, Zhu VW, Lopez PG, Amatu A, Doebele RC, Cassier P, Keam B, Schuler MH, Zhang H, Clifford C, Palmer M, Green J, Turner CD, Curigliano G (2020a) Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J Clin Oncol 38:109–109. https://doi.org/10.1200/jco.2020.38.15_suppl.109
Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F (2020b) State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol 38:1209–1221. https://doi.org/10.1200/JCO.19.02551
Subbiah V, Hu MI, Gainor JF, Mansfield AS, Alonso G, Taylor MH, Zhu VW, Garrido P, Amatu A, Doebele RC, Cassier P, Keam B, Schuler MH, Zhang H, Clifford C, Palmer M, Green J, Turner CD, Curigliano G (2021a) Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion-positive solid tumors. J Clin Oncol 39:467–467. https://doi.org/10.1200/JCO.2021.39.3_suppl.467
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH (2021b) Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 9(8):491–501. https://doi.org/10.1016/S2213-8587(21)00120-0
Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, Hu M, Cabanillas M, Behrang A, Meric-Bernstam F, Vo PTT, Mooers BHM, Wu J (2021c) Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol 32:261–268. https://doi.org/10.1016/j.annonc.2020.10.599
Tan L, Solomon BJ (2020) Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 31:1599–1600. https://doi.org/10.1016/j.annonc.2020.10.002
Terzyan SS, Shen T, Liu X, Huang Q, Teng P, Zhou M, Hilberg F, Cai J, Mooers BH, Wu J (2019) Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. J Biol Chem 294:10428–10437. https://doi.org/10.1074/jbc.RA119.007682
Tiedje V, Fagin JA (2020) Therapeutic breakthroughs for metastatic thyroid cancer. Nat Rev Endocrinol 16:77–78. https://doi.org/10.1038/s41574-019-0307-2
Timmins P (2020) Industry update: the latest developments in the field of therapeutic delivery. Ther Deliv 12:7–20. https://doi.org/10.4155/tde-2020-0124
Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13:1109–1120. https://doi.org/10.1677/erc.1.01120
University College (UC) (2020) Deciphering antitumour response and resistance with INtratumour heterogeneity. https://clinicaltrials.gov/ct2/show/NCT02314481?term=NCT02314481&draw=2&rank=1. Accessed 16 Mar 2020
Van Linden OP, Kooistra AJ, Leurs R, De Esch IJ, De Graaf C (2014) KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. J Med Chem 57:249–277. https://doi.org/10.1021/jm400378w
Wang Y, Sparidans RW, Potters S, Lebre MC, Beijnen JH, Schinkel AH (2021) ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacol Res 172:105850. https://doi.org/10.1016/j.phrs.2021.105850
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383:825–835. https://doi.org/10.1056/NEJMoa2005651
Wright KM (2021) FDA approves pralsetinib for treatment of adults with metastatic RET fusion-positive NSCLC. Oncology (Williston Park, NY) 34:406–431. https://doi.org/10.46883/onc.2020.3410.0406
Xia B, Ou SH (2020) Simultaneous RET solvent-front and gatekeeper resistance mutations in trans: a rare TKI-specific therapeutic challenge? J Thorac Oncol 15:479–481. https://doi.org/10.1016/j.jtho.2020.02.001
Yang SR, Aypar U, Rosen EY, Mata DA, Benayed R, Mullaney K, Jayakumaran G, Zhang Y, Frosina D, Drilon A, Ladanyi M, Jungbluth AA, Rekhtman N, Hechtman JF (2021) A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res 27(5):1316–1328. https://doi.org/10.1158/1078-0432.CCR-20-3208
Yu Y, Liu A, Dhawan G, Mei H, Zhang W, Izawa K, Soloshonok VA, Han J (2021) Fluorine-containing pharmaceuticals approved by the FDA in 2020: synthesis and biological activity. Chin Chem Lett. https://doi.org/10.1016/j.cclet.2021.05.042
Yuan S, Luo YQ, Zuo JH, Liu H, Li F, Yu B (2021) New drug approvals for 2020: synthesis and clinical applications. Eur J Med Chem 215:113284. https://doi.org/10.1016/j.ejmech.2021.113284
Zhou C (2020) Study of apatinib in RET fusion positive advanced non-small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT02540824?term=NCT02540824&draw=2&rank=1. Accessed 16 Mar 2020
Zhou Q, Wu Y, Chang J (2021) FP14.17 efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer after platinum-based chemotherapy. J Thorac Oncol 16:S235. https://doi.org/10.1016/j.jtho.2021.01.1629
Acknowledgements
The authors wish to convey their gratefulness to Botswana Medicines Regulatory Authority, Gaborone, Botswana. This work is not sponsored by any funding or organization.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare there is no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ali, F., Neha, K. & Chauhan, G. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers. Arch. Pharm. Res. 45, 309–327 (2022). https://doi.org/10.1007/s12272-022-01385-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-022-01385-3